Compare JBGS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBGS | DBVT |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.7M | 948.8M |
| IPO Year | 2017 | 2014 |
| Metric | JBGS | DBVT |
|---|---|---|
| Price | $14.96 | $17.35 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 627.5K | 306.8K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $13.71 | $8.51 |
| 52 Week High | $24.30 | $26.19 |
| Indicator | JBGS | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 51.29 |
| Support Level | $14.09 | $16.05 |
| Resistance Level | $15.29 | $17.36 |
| Average True Range (ATR) | 0.48 | 1.08 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 60.91 | 58.10 |
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.